MAM
ALXN

Melqart Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Melqart Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-885,384
Closed -$163M – 117
2021
Q2 		$163M Buy
885,384
+54,600
+7% +$9.37M 7.31% 3
2021
Q1 		$127M Buy
830,784
+415,384
+100% +$64.3M 5.76% 2
2020
Q4 		$64.9M Buy
+415,400
New +$53.4M 4.89% 4

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Melqart Asset Management's ALXN Position: Q3 2021 in Review

Melqart Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 885,384 shares — an estimated $163M sold.

Melqart Asset Management first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $163M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Melqart Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Melqart Asset Management sold 885,384 Alexion Pharmaceuticals shares in Q3 2021, an estimated $163M.
  • Melqart Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Melqart Asset Management's Alexion Pharmaceuticals position peaked at $163M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Melqart Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.